Event

AMTAR Seminar Series – Dr Yanling Lu & Dr Douglas Campbell (GlyTherix)

TIME: 12:00pm

WHEN: 21 March, 2025

LOCATION: AIBN Seminar Room and Zoom

TIMEZONE: AEST

My Journey from East to West and Beyond – Navigating a Career in Biotech and MedTech

Dr Yanling Lu – Head of CMC, GlyTherix Ltd

Yanling is a technical leader with strong expertise in biologics development and manufacturing. She was initially trained as an applied chemist in China and later obtained her Master and PhD degrees in Physical Biochemistry in the UK. Prior to moving to Australia in 2009, she was a Senior Scientist in Bioprocess Development at MedImmune Cambridge UK (now AstraZeneca) leading antibody characterisation and formulation development. In the last 18 years, Yanling has led R&D teams in the biotech sector across UK, US and Australia. She has a track record of bringing discovery projects through development to commercialisation with her versatile skills and experiences covering drug discovery and development, assay development, process development & CMC, cGMP biomanufacturing, clinical trials and regulatory.
Yanling was involved in the development of two commercial therapeutic antibody products and led commercialisation of two cancer diagnostic tests. Currently Yanling manages all CMC programs at GlyTherix to support preclinical and clinical development.

Dr Douglas Campbell – Head of R&D, GlyTherix Ltd

Douglas has 20 years experience in biomedical research with a particular focus on diagnostics, drug development and oncology. Douglas completed his PhD in cancer biology at the Garvan Institute of Medical Research. Following a postdoctoral position at Imperial Cancer Research Fund (now Cancer Research UK), Douglas joined Apollo Life Sciences as a team leader responsible for the development of recombinant protein expression and scale-up strategies. Douglas is Head of R&D at Minomic International Ltd and GlyTherix Ltd. Prior to Minomic, he was involved in the development of a novel antibody (MDX-1097) from pre-clinical to Phase 2 clinical trials.

Douglas is also a non-executive director of Drop Bio and co-founder of iClinix, a medical software company specialising in oncology, pharmacy and transplantation management systems.




VIEW ALL EVENTS